It’s been a mixed two weeks for small cap health companies, with 53 companies gaining ground, 64 losing it and 19 flatlining.

Here’s a table showing how ASX-listed healthcare stocks have been performing.

Rhythm Biosciences (ASX:RHY) was the biggest winner, up 33% after it shared an investors’ presentation deck this week which highlighted the imminent commercialisation of ColoSTAT, a technology that could detect the presence of protein markers in patients with colorectal cancer.

Tests have demonstrated a 33% higher accuracy than the current standard Faecal Immunochemical Test (FIT) used.

The company will soon make a submission to the Therapeutic Goods Administration (TGA), and is on track to receive the European CE mark by the end of the year.

Next cab off the ranks, up 25%, was cervical cancer screening company Truscreen (ASX:TRU) on last week’s news that its TruScreen device is now equipped with an improved cyber security upgrade, while flagging expanded distribution opportunities in China.

Vita Life Sciences (ASX:VLS) was up 24% on no news, and Actinogen Medical (ASX:ACW) was also up 23% after it released its September quarterly detailing the advance of the Xanamem clinical development pipeline and the filing of an Investigational New Drug submission to the US FDA for its FXS program.

And Dorsavi (ASX:DVL) was up 22% off the back of its quarterly reporting a 54% increase in revenue to $585,000 from the previous corresponding period.

The company believes that Q2 FY21 has a promising outlook with additional workers returning to the workplace and improved US site access.
 

Who flatlined?

Flat despite being granted a Chinese patent covering OPT-302 was Opthea Limited (ASX:OPT), and Zelira Therapeutics (ASX:ZLD) which raised US$5 million from a US fund.

Also flat was Pharmaxis (ASX:PXS) which does the first patient in its Phase 2 bone marrow cancer trial and Chimeric Therampeutics (ASX:CHM) which successfully completed manufacturing for CHM 2101 research grade plasmids – a critical first step in the development of CDH17 CAR T.
 

Who’s the biggest loser?

The biggest loser was a tie between Living Cell Tec (ASX:LCT) which dropped 20% despite signing a non-binding MOU with New Zealand biotechnology company NZeno for it to breed and maintain pigs to provide tissue for the upcoming third clinical trial of NTCELL in Parkinson’s disease – and Analytica Limited (ASX:ALT) which dropped 20% on no news.